Creyon Bio Appoints Venture Capitalists Serge Messerlian and Shaquille Vayda to Board of Directors
September 09, 2024 08:00 ET
|
Creyon Bio, Inc.
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Creyon Bio, Inc. ("Creyon"), a clinical-stage leader in AI/machine learning-enabled engineering of...
Creyon Bio Granted Second U.S. Patent for AI/Machine Learning-Enabled Oligonucleotide-Based Medicine Engineering Platform
September 04, 2024 08:00 ET
|
Creyon Bio, Inc.
Patent protects Creyon™ Platform’s proprietary method for rapid engineering and optimization of therapeutic oligonucleotides with AI/ML, accelerating development timelines Recent publication details...
Creyon Bio to Present Clinical Data on Rapid AI-Enabled Engineering of Oligonucleotide-Based Medicines at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
May 07, 2024 08:00 ET
|
Creyon Bio, Inc.
AI-informed drug design enabled approval to dose within one year of project initiation Data highlight use of AI to engineer investigative allele selective antisense oligonucleotide treatment for baby...
Creyon Bio and Cajal Neuroscience Announce Partnership to Develop Oligonucleotide-Based Medicines for Neurodegenerative Diseases
May 01, 2024 08:00 ET
|
Creyon Bio, Inc.
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C. and SEATTLE, May 01, 2024 (GLOBE NEWSWIRE) -- Creyon Bio, Inc. ("Creyon"), a drug development company that engineers Oligonucleotide-Based Medicines (OBMs)...